Proteinuria and Oral Gold Treatment
Authors: JUNIUS J. GONZALES
Journal: Annals of Internal Medicine (1985)

Letters and Corrections1 April 1985Proteinuria and Oral Gold TreatmentJUNIUS J. GONZALES, B.A., MINDY S. BOHRER, B.A., JONATHAN T. EDELSON, B.A., A. MARK FENDRICK, B.A., MARY F. MORRISON, B.S.JUNIUS J. GONZALES, B.A.Search for more papers by this author, MINDY S. BOHRER, B.A.Search for more papers by this author, JONATHAN T. EDELSON, B.A.Search for more papers by this author, A. MARK FENDRICK, B.A.Search for more papers by this author, MARY F. MORRISON, B.S.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-102-4-561 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptTo the editor: Katz and colleagues (1) have compiled an important and extensive review of proteinuria in patients with rheumatoid arthritis who are receiving oral gold treatments. We want to comment on two problems with this retrospective study and its conclusions.First, an analysis of potentially confounding disease variables in the study groups is needed to assess the actual contribution of gold treatment to proteinuria independent of other factors. The authors themselves cite the increased risk of proteinuria in patients with other nonrheumatologic disorders (such as diabetes mellitus, urinary tract infections, or congestive heart failure). Also, because at least two...References1. KATZ W, BLODGETT R, and PIETRUSKO R. Proteinuria in gold-treated rheumatoid arthritis. Ann Intern Med. 1984;101:176-9. LinkGoogle Scholar2. WARD J, WILLIAMS H, and EGGER M. Comparison of auranofin, gold sodium thiomalate, and placebo in the treatment of rheumatoid arthritis: a controlled clinical trial. Arthritis Rheum. 1983;26:1303-15. CrossrefMedlineGoogle Scholar3. KATZ W, ALEXANDER S, and BLAND J. The efficacy and safety of auranofin compared to placebo in rheumatoid arthritis. J Rheumatol [Suppl]. 1982;8:173-8. MedlineGoogle Scholar4. BRENNER B and RECTOR F. The Kidney. Philadelphia: W.B. Saunders Company; 1981. Google Scholar5. CLIVE D and STOFF J. Renal syndromes associated with nonsteroidal antiinflammatory drugs. N Engl J Med. 1984;310:563-572. CrossrefMedlineGoogle Scholar1. KATZ W, BLODGETT R, and PIETRUSKO R. Proteinuria in gold-treated rheumatoid arthritis. Ann Intern Med. 1985;101:176-9. LinkGoogle Scholar2. ABUELO J. Proteinuria: diagnostic principles and procedures. Ann Intern Med. 1983;98:186-91. LinkGoogle Scholar3. SAMUELS B, LEE J, ENGLEMAN E, and HOPPER J. Membranous nephropathy in patients with rheumatoid arthritis: relationship to gold therapy. Medicine (Baltimore). 1977;57:319-27. CrossrefGoogle Scholar4. WALLIN B, ZAREVICS P, and SCHEFFLER B. Six month response to auranofin in rheumatoid arthritis patients withdrawn from parenteral gold because of insufficient therapeutic effect (ITE) or adverse drug reactions (ADR) [Abstract]. Clin Res. 1984;32:724A. Google Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAuthors: JUNIUS J. GONZALES, B.A.; MINDY S. BOHRER, B.A.; JONATHAN T. EDELSON, B.A.; A. MARK FENDRICK, B.A.; MARY F. MORRISON, B.S.Affiliations: School of Medicine University of Pennsylvania Philadelphia, PA 19104 PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 1 April 1985Volume 102, Issue 4Page: 561-562KeywordsDiabetes mellitusFactor analysisHeart failureProteinuriaRetrospective studiesRheumatoid arthritis ePublished: 1 December 2008 Issue Published: 1 April 1985 PDF downloadLoading ...